EGFR and colonic neoplasm: Sulindac metabolites – sulindac sulfide (SS) and sulindac sulfone (SF) – also downregulate EGFR activation and/or expression in cancer cells, leading to attenuation of EGFR signaling in colon cancer cells (91).